Start main page content

Research Output



Palma, G. and Kaur, M. miRNA-128 and miRNA-223 regulate Cholesterol-Mediated Drug Resistance in Breast Cancer. IUBMB Life. (under production) 

Du Plessis, T.L., Abdulla, N. and Kaur, M., The Utility of 3D Models to Study Cholesterol in Cancer: Insights and Future Perspectives. Frontiers in Oncology13, p.1387. 


Kaur, M. and Dlamini, Z., 2022. Cholesterol and Cancer drug resistance: molecular, signalling and therapeutic aspects. Frontiers in Genetics, p.2141.

Lata, S., Saha, S.T., Kaur, M., Awolade, P., Ebenezer, O., Singh, P. and Kumar, V., 2022. Tetrahydro-β-carboline-naphthalimide hybrids: Synthesis and anti-proliferative evaluation on estrogen-dependent and triple-negative breast cancer cells. Journal of Molecular Structure1262, p.133053.

Palma, G.B.H. and Kaur, M., 2022. Cholesterol depletion modulates drug resistance pathways to sensitize resistant breast cancer cells to tamoxifen. Anticancer Research42(1), pp.565-579.

Monchusi, B. Kaur, M. miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to overcome Drug Resistance in Cancer. Curr Drug Targets. 2022. 23(6), pp. 656 - 677.


Abdulla, N., Vincent, C.T. and Kaur, M., 2021. Mechanistic insights delineating the role of cholesterol in epithelial mesenchymal transition and drug resistance in cancer. Frontiers in Cell and Developmental Biology, p.3282.

Khan, F., Radovanovic, A., Gojobori, T. and Kaur, M., 2021. IBDDB: a manually curated and text-mining-enhanced database of genes involved in inflammatory bowel disease. Database2021.

Monchusi, B. and Kaur, M., 2022. miRNAs as modulators of cholesterol in breast cancer stem cells: An approach to overcome drug resistance in cancer. Current drug targets23(6), pp.656-677.

Mabhida, S.E., Mashatola, L., Kaur, M., Sharma, J.R., Apalata, T., Muhamed, B., Benjeddou, M. and Johnson, R., 2021. Hypertension in African populations: review and computational insights. Genes12(4), p.532.


Sharma, B., Saha, S.T., Perumal, S., Gu, L., Ebenezer, O., Singh, P., Kaur, M. and Kumar, V., 2020. Design, Synthesis, Antiproliferative Evaluation, and Molecular Docking Studies of N-(3-Hydroxyindole)-Appended β-Carbolines/Tetrahydro-β-Carbolines Targeting Triple-Negative and Non-Triple-Negative Breast Cancer. ACS omega5(45), pp.28907-28917.

Rani, A., Singh, G.I., Kaur, R., Palma, G., Perumal, S., Kaur, M., Ebenezer, O., Awolade, P., Singh, P. and Kumar, V. (2020). Azide-alkyne cycloaddition en route to ferrocenyl-methoxy-methyl-isatin- conjugates: Synthesis, anti-breast cancer activities and molecular docking studies. Journal of Organometallic Chemistry, 907, p.121072.

Dhawan, S., Awolade, P., Kisten, P., Cele, N., Pillay, A.S., Saha, S., Kaur, M., Jonnalagadda, S.B. and Singh, P. (2020). Synthesis, cytotoxicity and antimicrobial evaluation of new coumarin‐tagged β‐lactam triazole hybrid. Chemistry & Biodiversity, 17(1), p.e1900462.

Vipan, K., Sharma, B., Gu, L., Pillay, R.P., Cele, N., Awolade, P., Singh, P., and Kaur, M. (2020). Design, Synthesis and anti-proliferative evaluation of 1H-1, 2, 3-triazole grafted tetrahydro-β-carboline-chalcone/ferrocenylchalcone conjugates in Estrogen Responsive and Triple Negative Breast Cancer cells. New Journal of Chemistry, 44, 11137-11147.

Monchusi, B., and Kaur, M. (2020). microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance. Genes & Cancer, 11:1-2.

Pankaj, S., Saha, S.T., Kaur, M., Oluwakemi, E., Awolade, P., Singh, P., and Kumar, V. (2020). Synthesis and in vitro anti-proliferative evaluation of naphthalimide–chalcone/pyrazoline conjugates as potential SERMs with computational validation. RSC Advances, 10 (27): 15836-15845.

Wellington, K.W., Hlatshwayo, V., Kolesnikova, N.I., Saha, S.T., Kaur, M., and Motadi, L.R. (2020). Anticancer activities of vitamin K3 analogues. Investigational New Drugs, 38:378–391.

Wellington, K.W., Kolesnikova, N.I., Hlatshwayo, V., Saha, ST., Kaur, M., Motadi, L.R. (2020). Anticancer activity, apoptosis and a structure–activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides. Invest New Drugs, 38:274–286.


Kumar, S., Palma, G., Perumal, S., Kaur, M., Singh-Pillay, A., Raj, R., Singh, P. and Kumar, V. (2019). Triarylethylene-indolin-2, 3-dione molecular conjugates: design, synthesis, docking studies and anti-proliferation evaluation. RSC Advances, 9(72), pp.42409-42414.

Gu, L., Saha, S. T., Thomas, J., & Kaur, M. (2019). Targeting cellular cholesterol for anticancer therapy. The FEBS journal, 286(21), 4192-4208.

Sharma, B., Singh, A., Gu, L., Saha, S.T., Singh-Pillay, A., Cele, N., Singh, P., Kaur, M. and Kumar, V. (2019). Diastereoselective approach to rationally design tetrahydro-β-carboline–isatin conjugates as potential SERMs against breast cancer. RSC advances, 9(17), pp.9809-9819.

Esau, L., Zhang, G., Sagar, S., Stingl, U., Bajic, V. B., & Kaur, M. (2019). Mining the deep Red-Sea brine pool microbial community for anticancer therapeutics. BMC complementary and alternative medicine, 19(1), 1-10.


Saha, S.T. and Kaur, M. (2018). Delving KS-01 as a novel therapeutic strategy in treating breast cancer. Sept, 2018, Journal of Global Oncology 4, no. Supplement 2. DOI: 10.1200/jgo.18.29900.

Kumar S., Gu L., Palma G., Kaur M., Singh-Pillay A., Singh P., Kumar V. (2018). Design, synthesis, anti-proliferative evaluation and docking studies of 1H-1,2,3-triazole tethered ospemifene–isatin conjugates as selective estrogen receptor modulators. New Journal of Chemistry. 42, 3703-3713.

Kumar, S., Saha, S., Gu, L., Palma, G., Perumal, S., Singh-Pillay, A., Singh, P., Anand, A., Kaur, M and Kumar, V. (2018). 1H-1,2,3-Triazole Tethered Nitroimidazole–Isatin Conjugates: Synthesis, Docking, and Anti-Proliferative Evaluation against Breast Cancer. ACS Omega. 3(9), 12106-12113.

Dhawan, S., Kerru, N., Awolade, P., Singh-Pillay, A., Saha, S.T., Kaur, M., Jonnalagadda, S.B. and Singh, P. (2018). Synthesis, computational studies and antiproliferative activities of coumarin-tagged 1, 3, 4-oxadiazole conjugates against MDA-MB-231 and MCF-7 human breast cancer cells. Bioorganic & medicinal chemistry. 26(21), 5612-5623.

Singh, A., Saha, S.T., Perumal, S., Kaur, M. and Kumar, V. (2018). Azide–Alkyne Cycloaddition En Route to 1 H-1, 2, 3-Triazole-Tethered Isatin–Ferrocene, Ferrocenylmethoxy–Isatin, and Isatin–Ferrocenylchalcone Conjugates: Synthesis and Antiproliferative Evaluation. ACS Omega. 3(1), 1263-1268.


Kaur M, Abdulla N, Aronson A, Perumal S. KS-01 as a cancer therapy neoadjuvant or adjuvant. Provisional patent no: 2022/08061, filed 20th July 2022.

Kaur M., and Saha S. KS-01 for use in the treatment of breast cancer. PCT patent application no: PCT/IN2020/050651. 28 January 2020.